Laboratory Corporation of America Holdings (LabCorp) is in talks to acquire contract researcher Pharmaceutical Product Development LLC (PPD) for more than $8 billion, including debt, people familiar with the matter said on Friday.
Such a deal would be LabCorp’s largest acquisition ever, advancing its strategy of combining laboratory testing services under one corporate umbrella following its acquisition of contract research organization Covance Inc in 2015 for $5.7 billion.
LabCorp was just one of the parties participating in an auction for private equity-owned PPD, which has also attracted interest from buyout firms, the people said. The people added that there was no certainty that LabCorp would clinch a deal, and any agreement might not come for several more weeks.
The sources asked not to be identified because the deliberations were confidential. LabCorp and PPD did not immediately respond to requests for comment. PPD’s owners, Carlyle Group LP and Hellman & Friedman LLC, declined to comment.
Based in Wilmington, North Carolina, PPD offers its services to biotech, pharmaceutical and medical device companies that want to outsource research services. It focuses its research on a wide range of therapeutic areas, ranging from cardiovascular to urology.
Carlyle and Hellman & Friedman took the company private in 2011 for $3.9 billion.
Headquartered in Burlington, North Carolina, LabCorp is one of the largest independent clinical laboratory companies in the United States. It offers tests used in routine testing, patient diagnosis and in the monitoring and treatment of disease.
In addition, the company has developed specialty testing such as oncology testing, HIV genotyping and phenotyping, diagnostic genetics and clinical trials. It has a market capitalization of $14.1 billion.
Recent deals among clinical contract researchers have included a merger of Quintiles, a publicly traded contract researcher, and IMS Holdings, a medical data provider, in a $10 billion deal that created a new company, IMS Quintiles Holdings.
By Carl O’Donnell and Greg Roumeliotis
Source: Reuters
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
